aBLA Filing Intelligence & Biosimilar Opportunity

Ziihera

Zanidatamab-Hrii

Anticancer

Intravenous Infusion

Ziihera is the first and only approved bispecific antibody drug. It treats unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. This drug is given to patients who have already received the other chemotherapeutic treatment.

Approval Date

20-Nov-24

Data Exclusivity Expiry

20-Nov-28

Market Exclusivity Expiry

20-Nov-36

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

154.63%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

106

2027

365

2028

703

2029

1,051

2030

1,446

2031

1,826

2032

2,158

Molecule profile

Details & specifications

Molecule

Zanidatamab-Hrii

Innovator

JAZZ PHARMACEUTICALS

Dosage Form

Intravenous Infusion

Strength

30 mg/vial

Therapeutic Category

Anticancer

Usage

To treat unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets